Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

about

A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models.

P2860

Q52655032-4582BB90-74F9-4180-BE0B-79879979ED7D

P2860

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

Item

http://www.wikidata.org/entity/Q38298124

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

@en

type

Item

label

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

@en

prefLabel

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

@en

P1476

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

@en

P2093

Elizabeth Hovey

http://www.w3.org/2001/XMLSchema#string

Kerrie L McDonald

http://www.w3.org/2001/XMLSchema#string

Oliver Carleton

http://www.w3.org/2001/XMLSchema#string

Sara Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

The somatic genomic landscape of glioblastoma

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca

P2888

s13277-014-2960-3

P304

153-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-014-2960-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Toni R. Jue

P577

2014-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004381519

http://www.w3.org/2001/XMLSchema#string

P698

25534238

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

about

P2860

P2860

Incorporation of biomarkers in phase II studies of recurrent glioblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921